6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Carbamazepine
This drug is used to treat epilepsy and diseases that induce seizures because it contains anticonvulsant characteristics. It is the medication that is prescribed in oral dose forms available including chewable tablets, immediate-release tablets, extended-release tablets, and extended-release capsules. There is also an intravenous (IV) form available. It is also a generic medication. Oftentimes, generic drugs are less expensive than name brands. The brand-name medicine may not always be available in every dose form or strength. Schizophrenia is also treated with it in combination with several medications. It is furthermore used as a second-line drug for the treatment of the bipolar disorder. Some common side effects of carbamazepine include constipation, tiredness, drowsiness, and disorders of voluntary movement.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Michelle Charbonnier
MoNetwork, United States
Monica Zuniga Fajuri
Tiburcio Vasquez Health Center, United StatesSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Gangstalking is real, should be studied
Sam Vaknin, Southern Federal University, United Kingdom
Title : Decoding aggression, violence, and substance use in adolescents with conduct disorders: Neurochemical pathways and interventions
Ann Marie Leonard Zabel, Curry College, United States
Title : Sensoria driven genetic decoupling and impaired areal integration in diseases of agency
Denis Larrivee, University of Navarra, Spain
Title : Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: A longitudinal study
Elizabeth Dale Gilley, The Elle Foundation, United States